You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameProchlorperazine
Accession NumberDB00433  (APRD00624)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612)
Structure
Thumb
Synonyms
2-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)-phenothiazine
2-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
3-Chloro-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine
3-Chloro-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine
Capazine
Chlormeprazine
Chloro-3 (N-methylpiperazinyl-3 propyl)-10 phenothiazine
Chloropernazine
Emetiral
N-(gamma-(4'-Methylpiperazinyl-1')propyl)-3-chlorophenothiazine
Prochlorperazin
Prochlorpérazine
Prochlorperazinum
Prochlorpermazine
Prochlorpromazine
Procloperazine
Proclorperazina
External Identifiers
  • Bayer A 173
  • RP 6140
  • SKF 4657
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Nu-prochlor Tab 10mgtablet10 mgoralNu Pharm Inc1992-12-312012-09-04Canada
Nu-prochlor Tab 5mgtablet5 mgoralNu Pharm Inc1992-12-312012-09-04Canada
PMS Prochlorperazine Inj 5mg/mlsolution5 mgintramuscular; intravenousPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Suppositoires 10mgsuppository10 mgrectalPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Tab 10mgtablet10 mgoralPharmascience Inc1989-12-31Not applicableCanada
PMS-prochlorperazine Tab 5mgtablet5 mgoralPharmascience Inc1989-12-31Not applicableCanada
Prochlorazinetablet10 mgoralAa Pharma Inc2000-02-09Not applicableCanada
Prochlorazinetablet5 mgoralAa Pharma Inc2000-02-09Not applicableCanada
Prochlorperazine Mesylate Inj 5mg/mlliquid5 mgintramuscular; intravenousSandoz Canada Incorporated1989-12-31Not applicableCanada
Sandoz Prochlorperazinesuppository10 mgrectalSandoz Canada Incorporated1989-12-31Not applicableCanada
Stemetilsolution5 mgintramuscular; intravenousSanofi Aventis Canada Inc1957-12-312007-01-30Canada
Stemetilsuppository10 mgrectalSanofi Aventis Canada Inc1958-12-312006-07-28Canada
Stemetil Liq 5mg/5mlsyrup5 mgoralAventis Pharma Inc1958-12-312005-08-01Canada
Stemetil Tab 10mgtablet10 mgoralAventis Pharma Inc1957-12-312005-08-01Canada
Stemetil Tab 5mgtablet5 mgoralAventis Pharma Inc1957-12-312005-08-01Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Compazinetablet, film coated10 mg/1oralPBM Pharmaceuticals, Inc.2014-04-012016-01-31Us
Compazinesuppository25 mg/1rectalPBM Pharmaceuticals, Inc2013-07-01Not applicableUs
Compazinetablet, film coated5 mg/1oralPBM Pharmaceuticals, Inc.2014-04-012016-01-27Us
Comprosuppository25 mg/1rectalPd Rx Pharmaceuticals, Inc.2000-09-01Not applicableUs
Comprosuppository25 mg/1rectalPaddock Laboratories, LLC2000-09-01Not applicableUs
Prochlorperazinetablet10 mg/1oralSTAT Rx USA LLC2009-07-29Not applicableUs
Prochlorperazinesuppository25 mg/1rectalPhysicians Total Care, Inc.2001-07-20Not applicableUs
Prochlorperazinesuppository25 mg/1rectalG&W Laboratories, Inc.1993-11-30Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousHeritage Pharmaceuticals Inc.2015-01-14Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousCardinal Health2012-03-26Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousBaxter Healthcare Corporation2011-01-14Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscularREMEDYREPACK INC.2015-03-12Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousHeritage Pharmaceuticals Inc.2015-06-26Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousWest Ward Pharmaceuticals Corp.1989-08-29Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousPhysicians Total Care, Inc.2004-07-26Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousCardinal Health2004-07-26Not applicableUs
Prochlorperazine Edisylateinjection5 mg/mLintramuscular; intravenousHeritage Pharmaceuticals Inc.2012-03-26Not applicableUs
Prochlorperazine Edisylateinjection10 mg/2mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-08-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-13Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralAidarex Pharmaceuticals LLC1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralA S Medication Solutions Llc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralCardinal Health1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralAvera Mc Kennan Hospital2015-09-08Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralTeva Pharmaceuticals USA Inc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralSandoz Inc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-13Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralREMEDYREPACK INC.2012-09-12Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc.2013-03-14Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralLiberty Pharmaceuticals, Inc.1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralbryant ranch prepack1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralMylan Institutional Inc.1997-04-15Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralLake Erie Medical & Surgical Supply DBA Quality Care Prodcuts LLC2011-12-06Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralRebel Distributors Corp1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralAvera Mc Kennan Hospital2015-05-20Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralTeva Pharmaceuticals USA Inc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralSandoz Inc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.1996-11-18Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-13Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralPreferred Pharmaceuticals, Inc.2012-07-26Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-07-19Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralPhysicians Total Care, Inc.2003-02-10Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralbryant ranch prepack1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralLake Erie Medical DBA Quality Care Products LLC2012-11-05Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralMylan Institutional Inc.1997-04-15Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralCardinal Health2011-01-28Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralDispensing Solutions, Inc.1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralMylan Pharmaceuticals Inc.1996-11-18Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralRebel Distributors Corp1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-11-18Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralProficient Rx LP1998-03-01Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralBlenheim Pharmacal, Inc.2013-11-18Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralREMEDYREPACK INC.2011-04-11Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralREMEDYREPACK INC.2013-06-03Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-13Not applicableUs
Prochlorperazine Maleatetablet10 mg/1oralPreferred Pharmaceuticals, Inc.2014-05-13Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2010-12-13Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralAidarex Pharmaceuticals LLC1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralA S Medication Solutions Llc1996-07-25Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralPd Rx Pharmaceuticals, Inc.2010-12-13Not applicableUs
Prochlorperazine Maleatetablet5 mg/61oralNorthwind Pharmaceuticals2014-04-28Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralCardinal Health2011-01-28Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralAmerican Health Packaging2014-09-292016-01-31Us
Prochlorperazine Maleatetablet, film coated10 mg/1oralMylan Pharmaceuticals Inc.1996-11-18Not applicableUs
Prochlorperazine Maleatetablet, film coated5 mg/1oralA S Medication Solutions Llc1996-11-18Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralPhysicians Total Care, Inc.2000-01-07Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralProficient Rx LP1998-03-01Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralBlenheim Pharmacal, Inc.2011-04-01Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralREMEDYREPACK INC.2011-06-30Not applicableUs
Prochlorperazine Maleatetablet5 mg/1oralJUBILANT CADISTA PHARMACEUTICALS, INC.1998-03-01Not applicableUs
Prochlorperazine Maleatetablet, film coated10 mg/1oralPreferred Pharmaceuticals, Inc2012-04-05Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BuccastemReckitt Benckiser
EmetiralZentiva
StemzineSanofi-Aventis
VoliminChin Teng
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Prochlorperazine dimaleate
ThumbNot applicableDBSALT001627
Prochlorperazine edisylate
ThumbNot applicableDBSALT000999
Prochlorperazine maleate
ThumbNot applicableDBSALT000998
Categories
UNIIYHP6YLT61T
CAS number58-38-8
WeightAverage: 373.943
Monoisotopic: 373.13794618
Chemical FormulaC20H24ClN3S
InChI KeyInChIKey=WIKYUJGCLQQFNW-UHFFFAOYSA-N
InChI
InChI=1S/C20H24ClN3S/c1-22-11-13-23(14-12-22)9-4-10-24-17-5-2-3-6-19(17)25-20-8-7-16(21)15-18(20)24/h2-3,5-8,15H,4,9-14H2,1H3
IUPAC Name
2-chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine
SMILES
CN1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(Cl)C=C3)CC1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • N-alkylpiperazine
  • N-methylpiperazine
  • Piperazine
  • 1,4-diazinane
  • Aryl halide
  • Aryl chloride
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Organochloride
  • Organohalogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the symptomatic management of psychotic disorders, short term management of nonpsychotic anxiety in patients with generalized anxiety disorder, and for the control of severe nausea and vomiting of various causes.
PharmacodynamicsProchlorperazine is a piperazine phenothiazine related to high-potency neuroleptics such as perphenazine. It shares many of the actions and adverse effects of the antipsychotics.
Mechanism of actionThe mechanism of action of prochlorperazine has not been fully determined, but may be primarily related to its antidopaminergic effects. Prochlorperazine blocks the D2 somatodendritic autoreceptor, resulting in the blockade of postsynaptic dopamine receptors in the mesolimbic system and an increased dopamine turnover. Prochlorperazine also has anti-emetic effects, which can be attributed to dopamine blockade in the chemoreceptor trigger zone. Prochlorperazine also blocks anticholinergic and alpha-adrenergic receptors, the blockade of alpha(1)-adrenergic receptors resulting in sedation, muscle relaxation, and hypotension.
Related Articles
AbsorptionRapidly absorbed following oral administration
Volume of distributionNot Available
Protein binding91-99%
Metabolism

Hepatic. Undergoes metabolism in the gastric mucosa and on first pass through the liver, CYP2D6 and/or CYP3A4.

Route of eliminationNot Available
Half life6 to 8 hours
ClearanceNot Available
ToxicitySymptoms of central nervous system depression to the point of somnolence or coma. Agitation and restlessness may also occur. Other possible manifestations include convulsions, EKG changes and cardiac arrhythmias, fever and autonomic reactions such as hypotension, dry mouth and ileus; LD50=400mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9821
Blood Brain Barrier+0.9781
Caco-2 permeable+0.7729
P-glycoprotein substrateSubstrate0.8537
P-glycoprotein inhibitor IInhibitor0.817
P-glycoprotein inhibitor IIInhibitor0.8577
Renal organic cation transporterInhibitor0.7615
CYP450 2C9 substrateNon-substrate0.7702
CYP450 2D6 substrateNon-substrate0.5179
CYP450 3A4 substrateNon-substrate0.5346
CYP450 1A2 substrateInhibitor0.9376
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorInhibitor0.9723
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorNon-inhibitor0.7676
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8557
Ames testNon AMES toxic0.8999
CarcinogenicityNon-carcinogens0.9456
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.3496 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8165
hERG inhibition (predictor II)Inhibitor0.786
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Glaxosmithkline
  • Paddock laboratories inc
  • Able laboratories inc
  • G and w laboratories inc
  • Alpharma us pharmaceuticals division
  • Morton grove pharmaceuticals inc
  • Baxter healthcare corp anesthesia and critical care
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
  • Cadista pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Suppositoryrectal25 mg/1
Solutionintramuscular; intravenous5 mg
Suppositoryrectal10 mg
Tabletoral10 mg
Tabletoral5 mg
Injectionintramuscular5 mg/mL
Injectionintramuscular; intravenous10 mg/2mL
Injectionintramuscular; intravenous5 mg/mL
Tabletoral10 mg/1
Tabletoral5 mg/61
Tabletoral5 mg/1
Tablet, film coatedoral10 mg/1
Tablet, film coatedoral5 mg/1
Liquidintramuscular; intravenous5 mg
Syruporal5 mg
Prices
Unit descriptionCostUnit
Prochlorperazine mal powder4.77USD g
Compazine 25 mg suppository4.25USD suppository
Prochlorperazine 25 mg suppository3.13USD suppository
Compro 25 mg suppository3.05USD suppository
Compazine 5 mg tablet1.82USD tablet
Compazine 10 mg tablet1.8USD tablet
Prochlorperazine 5 mg/ml vial1.22USD ml
Prochlorperazine 5 mg/ml0.91USD ml
Prochlorperazine Maleate 10 mg tablet0.88USD tablet
Sandoz Prochlorperazine 10 mg Suppository0.87USD suppository
Prochlorperazine 10 mg tablet0.85USD tablet
Prochlorperazine Maleate 5 mg tablet0.59USD tablet
Prochlorperazine 5 mg tablet0.57USD tablet
Apo-Prochlorazine 10 mg Tablet0.21USD tablet
Apo-Prochlorazine 5 mg Tablet0.17USD tablet
Novamine 15% iv solution0.09USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point228 °CPhysProp
water solubility15 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.88HANSCH,C ET AL. (1995)
logS-4.4ADME Research, USCD
pKa8.1SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.011 mg/mLALOGPS
logP4.67ALOGPS
logP4.38ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.39ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area9.72 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity109.81 m3·mol-1ChemAxon
Polarizability41.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10.4 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-022c-9752000000-533ac31876b44d82f2aaView in MoNA
References
Synthesis Reference

DrugSyn.org

US2902484
General ReferencesNot Available
External Links
ATC CodesN05AB04
AHFS Codes
  • 28:16.08.24
  • 56:22.08
PDB EntriesNot Available
FDA labelDownload (617 KB)
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineProchlorperazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineProchlorperazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Prochlorperazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with 7-Nitroindazole.
AbirateroneThe metabolism of Prochlorperazine can be decreased when combined with Abiraterone.
AcebutololProchlorperazine may increase the hypotensive activities of Acebutolol.
AcepromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aceprometazine.
adipiplonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Agomelatine.
AlfaxaloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Alfaxalone.
AlfentanilProchlorperazine may increase the hypotensive activities of Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Prochlorperazine.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Prochlorperazine.
AlphacetylmethadolProchlorperazine may increase the hypotensive activities of Alphacetylmethadol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Prochlorperazine.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prochlorperazine.
AlprenololProchlorperazine may increase the hypotensive activities of Alprenolol.
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AmiodaroneThe metabolism of Prochlorperazine can be decreased when combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Prochlorperazine.
AmobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amobarbital.
AmodiaquineThe serum concentration of Prochlorperazine can be increased when it is combined with Amodiaquine.
AmoxapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Amperozide.
AmphetamineProchlorperazine may decrease the stimulatory activities of Amphetamine.
AprepitantThe serum concentration of Prochlorperazine can be increased when it is combined with Aprepitant.
AripiprazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Aripiprazole.
ArotinololProchlorperazine may increase the hypotensive activities of Arotinolol.
ArtemetherThe serum concentration of Prochlorperazine can be increased when it is combined with Artemether.
ArtesunateThe serum concentration of Prochlorperazine can be increased when it is combined with Artesunate.
ArticaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Asenapine.
AtazanavirThe metabolism of Prochlorperazine can be decreased when combined with Atazanavir.
AtenololProchlorperazine may increase the hypotensive activities of Atenolol.
AtomoxetineThe metabolism of Prochlorperazine can be decreased when combined with Atomoxetine.
AtovaquoneThe serum concentration of Prochlorperazine can be increased when it is combined with Atovaquone.
AzaperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Azaperone.
AzelastineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Prochlorperazine.
BaclofenThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Barbital.
BefunololProchlorperazine may increase the hypotensive activities of Befunolol.
BenzocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzocaine.
BenzphetamineProchlorperazine may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Benzyl alcohol.
BetaxololProchlorperazine may increase the hypotensive activities of Betaxolol.
BetaxololThe metabolism of Prochlorperazine can be decreased when combined with Betaxolol.
BevantololProchlorperazine may increase the hypotensive activities of Bevantolol.
BexaroteneThe serum concentration of Prochlorperazine can be decreased when it is combined with Bexarotene.
BezitramideProchlorperazine may increase the hypotensive activities of Bezitramide.
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
BisoprololProchlorperazine may increase the hypotensive activities of Bisoprolol.
BoceprevirThe metabolism of Prochlorperazine can be decreased when combined with Boceprevir.
BopindololProchlorperazine may increase the hypotensive activities of Bopindolol.
BortezomibThe metabolism of Prochlorperazine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Prochlorperazine can be decreased when it is combined with Bosentan.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
BrimonidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Bromazepam.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Prochlorperazine.
BrompheniramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Brotizolam.
BufuralolProchlorperazine may increase the hypotensive activities of Bufuralol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Prochlorperazine.
BupranololProchlorperazine may increase the hypotensive activities of Bupranolol.
BuprenorphineProchlorperazine may increase the hypotensive activities of Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Prochlorperazine.
BupropionThe metabolism of Prochlorperazine can be decreased when combined with Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Prochlorperazine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Prochlorperazine.
ButacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Butethal.
ButorphanolProchlorperazine may increase the hypotensive activities of Butorphanol.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Prochlorperazine.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Prochlorperazine.
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
CarbamazepineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carbinoxamine.
CarfentanilProchlorperazine may increase the hypotensive activities of Carfentanil.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Prochlorperazine.
CarisoprodolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carisoprodol.
CarteololProchlorperazine may increase the hypotensive activities of Carteolol.
CarvedilolProchlorperazine may increase the hypotensive activities of Carvedilol.
CelecoxibThe metabolism of Prochlorperazine can be decreased when combined with Celecoxib.
CeliprololProchlorperazine may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Prochlorperazine can be increased when it is combined with Ceritinib.
CetirizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloral hydrate.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloroprocaine.
ChloroquineThe serum concentration of Prochlorperazine can be increased when it is combined with Chloroquine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorphenamine.
ChlorphentermineProchlorperazine may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe metabolism of Prochlorperazine can be decreased when combined with Chlorpromazine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorprothixene.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Prochlorperazine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of Prochlorperazine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Prochlorperazine can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cinchocaine.
CitalopramThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Citalopram.
ClarithromycinThe metabolism of Prochlorperazine can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Prochlorperazine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clemastine.
ClidiniumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clidinium.
ClobazamThe metabolism of Prochlorperazine can be decreased when combined with Clobazam.
ClobazamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonazepam.
ClonidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clonidine.
ClorazepateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clorazepate.
ClotrimazoleThe metabolism of Prochlorperazine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of Prochlorperazine can be decreased when combined with Clozapine.
ClozapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Clozapine.
CobicistatThe serum concentration of Prochlorperazine can be increased when it is combined with Cobicistat.
CocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cocaine.
CodeineProchlorperazine may increase the hypotensive activities of Codeine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Prochlorperazine.
ConivaptanThe serum concentration of Prochlorperazine can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Prochlorperazine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prochlorperazine.
CyclosporineThe metabolism of Prochlorperazine can be decreased when combined with Cyclosporine.
CyproheptadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyproheptadine.
DabrafenibThe serum concentration of Prochlorperazine can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dantrolene.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Prochlorperazine.
DapoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dapoxetine.
DapsoneThe serum concentration of Prochlorperazine can be increased when it is combined with Dapsone.
DarifenacinThe metabolism of Prochlorperazine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Prochlorperazine can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Prochlorperazine can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Prochlorperazine can be decreased when it is combined with Deferasirox.
DeferoxamineThe risk or severity of adverse effects can be increased when Deferoxamine is combined with Prochlorperazine.
DelavirdineThe metabolism of Prochlorperazine can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Prochlorperazine.
DesloratadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Prochlorperazine.
DetomidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Detomidine.
DexamethasoneThe serum concentration of Prochlorperazine can be decreased when it is combined with Dexamethasone.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexbrompheniramine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dexmedetomidine.
DextroamphetamineProchlorperazine may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Prochlorperazine.
DextromoramideProchlorperazine may increase the hypotensive activities of Dextromoramide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Prochlorperazine.
DextropropoxypheneProchlorperazine may increase the hypotensive activities of Dextropropoxyphene.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prochlorperazine.
DezocineProchlorperazine may increase the hypotensive activities of Dezocine.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Prochlorperazine.
DiazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diazepam.
DifenoxinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Difenoxin.
DihydrocodeineProchlorperazine may increase the hypotensive activities of Dihydrocodeine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prochlorperazine.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prochlorperazine.
DihydroetorphineProchlorperazine may increase the hypotensive activities of Dihydroetorphine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Prochlorperazine.
DihydromorphineProchlorperazine may increase the hypotensive activities of Dihydromorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Prochlorperazine.
DiltiazemThe metabolism of Prochlorperazine can be decreased when combined with Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dimenhydrinate.
DiphenhydramineThe metabolism of Prochlorperazine can be decreased when combined with Diphenhydramine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Diphenhydramine.
DiphenoxylateProchlorperazine may increase the hypotensive activities of Diphenoxylate.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prochlorperazine.
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Prochlorperazine.
DoramectinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doramectin.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Prochlorperazine.
DoxycyclineThe serum concentration of Prochlorperazine can be increased when it is combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
DoxylamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Doxylamine.
DPDPEProchlorperazine may increase the hypotensive activities of DPDPE.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Prochlorperazine.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
DronedaroneThe metabolism of Prochlorperazine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Droperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Drotebanol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Prochlorperazine.
DyclonineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with ECGONINE METHYL ESTER.
EfavirenzThe serum concentration of Prochlorperazine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Efavirenz.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Prochlorperazine.
EliglustatThe metabolism of Prochlorperazine can be decreased when combined with Eliglustat.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Prochlorperazine.
EntacaponeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Entacapone.
EnzalutamideThe serum concentration of Prochlorperazine can be decreased when it is combined with Enzalutamide.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Prochlorperazine.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Prochlorperazine.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Prochlorperazine.
ErythromycinThe metabolism of Prochlorperazine can be decreased when combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Escitalopram.
Eslicarbazepine acetateThe serum concentration of Prochlorperazine can be decreased when it is combined with Eslicarbazepine acetate.
EsmololProchlorperazine may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Prochlorperazine.
EthanolProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Prochlorperazine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prochlorperazine.
EthosuximideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl loflazepate.
EthylmorphineProchlorperazine may increase the hypotensive activities of Ethylmorphine.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Prochlorperazine.
EtidocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Prochlorperazine.
EtoperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etoperidone.
EtorphineProchlorperazine may increase the hypotensive activities of Etorphine.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Prochlorperazine.
EtravirineThe serum concentration of Prochlorperazine can be decreased when it is combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ezogabine.
FelbamateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Felbamate.
FencamfamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fenfluramine.
FentanylProchlorperazine may increase the hypotensive activities of Fentanyl.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Prochlorperazine.
FexofenadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flibanserin.
FluconazoleThe metabolism of Prochlorperazine can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fludiazepam.
FlunarizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunarizine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fluvoxamine.
FosamprenavirThe metabolism of Prochlorperazine can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Prochlorperazine can be increased when it is combined with Fosaprepitant.
FosphenytoinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Prochlorperazine.
Fusidic AcidThe serum concentration of Prochlorperazine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Glutethimide.
GuanfacineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halazepam.
HalofantrineThe serum concentration of Prochlorperazine can be increased when it is combined with Halofantrine.
HaloperidolThe metabolism of Prochlorperazine can be decreased when combined with Haloperidol.
HaloperidolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halothane.
HeroinProchlorperazine may increase the hypotensive activities of Heroin.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Prochlorperazine.
HexobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hexobarbital.
HydrocodoneProchlorperazine may increase the hypotensive activities of Hydrocodone.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Prochlorperazine.
HydromorphoneProchlorperazine may increase the hypotensive activities of Hydromorphone.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Prochlorperazine.
Hydroxyamphetamine hydrobromideProchlorperazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxychloroquineThe serum concentration of Prochlorperazine can be increased when it is combined with Hydroxychloroquine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
HydroxyzineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Hydroxyzine.
IdelalisibThe serum concentration of Prochlorperazine can be increased when it is combined with Idelalisib.
IloperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Iloperidone.
ImatinibThe metabolism of Prochlorperazine can be decreased when combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Prochlorperazine.
IndalpineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Indalpine.
IndenololProchlorperazine may increase the hypotensive activities of Indenolol.
IndinavirThe metabolism of Prochlorperazine can be decreased when combined with Indinavir.
IsavuconazoniumThe metabolism of Prochlorperazine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Prochlorperazine.
IsofluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Isoflurane.
IsoniazidThe metabolism of Prochlorperazine can be decreased when combined with Isoniazid.
IsradipineThe metabolism of Prochlorperazine can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Prochlorperazine can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Prochlorperazine can be increased when it is combined with Ivacaftor.
KetamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ketazolam.
KetobemidoneProchlorperazine may increase the hypotensive activities of Ketobemidone.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Prochlorperazine.
KetoconazoleThe metabolism of Prochlorperazine can be decreased when combined with Ketoconazole.
LabetalolProchlorperazine may increase the hypotensive activities of Labetalol.
LamotrigineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lamotrigine.
LevetiracetamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levetiracetam.
LevobunololProchlorperazine may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levodopa.
Levomethadyl AcetateProchlorperazine may increase the hypotensive activities of Levomethadyl Acetate.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Prochlorperazine.
LevomilnacipranThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Levomilnacipran.
LevorphanolProchlorperazine may increase the hypotensive activities of Levorphanol.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Prochlorperazine.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Prochlorperazine.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Prochlorperazine.
LisdexamfetamineProchlorperazine may decrease the stimulatory activities of Lisdexamfetamine.
LithiumLithium may increase the neurotoxic activities of Prochlorperazine.
LithiumThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lithium.
LofentanilProchlorperazine may increase the hypotensive activities of Lofentanil.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Prochlorperazine.
LopinavirThe metabolism of Prochlorperazine can be decreased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Prochlorperazine.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Prochlorperazine.
LovastatinThe metabolism of Prochlorperazine can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Prochlorperazine.
Lu AA21004The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Prochlorperazine can be increased when it is combined with Luliconazole.
LumefantrineThe serum concentration of Prochlorperazine can be increased when it is combined with Lumefantrine.
LurasidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Lurasidone.
MagaldrateMagaldrate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Magnesium Sulfate.
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Prochlorperazine.
MeclizineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Medetomidine.
MefloquineThe serum concentration of Prochlorperazine can be increased when it is combined with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Melperone.
MephentermineProchlorperazine may decrease the stimulatory activities of Mephentermine.
MepivacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Prochlorperazine.
MequitazineProchlorperazine may increase the arrhythmogenic activities of Mequitazine.
MesoridazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Metaxalone.
MethadoneProchlorperazine may increase the hypotensive activities of Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Prochlorperazine.
Methadyl AcetateProchlorperazine may increase the hypotensive activities of Methadyl Acetate.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Prochlorperazine.
MethamphetamineProchlorperazine may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methohexital.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methylphenobarbital.
MetipranololProchlorperazine may increase the hypotensive activities of Metipranolol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Prochlorperazine.
MetoprololProchlorperazine may increase the hypotensive activities of Metoprolol.
MetoprololThe metabolism of Prochlorperazine can be decreased when combined with Metoprolol.
MetyrosineProchlorperazine may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Prochlorperazine.
MidazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Midazolam.
MifepristoneThe metabolism of Prochlorperazine can be decreased when combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
MirabegronThe metabolism of Prochlorperazine can be decreased when combined with Mirabegron.
MirtazapineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Prochlorperazine.
MitotaneThe serum concentration of Prochlorperazine can be decreased when it is combined with Mitotane.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Prochlorperazine.
ModafinilThe serum concentration of Prochlorperazine can be decreased when it is combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Molindone.
MorphineProchlorperazine may increase the hypotensive activities of Morphine.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Prochlorperazine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.
NabiloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nabilone.
NadololProchlorperazine may increase the hypotensive activities of Nadolol.
NafcillinThe serum concentration of Prochlorperazine can be decreased when it is combined with Nafcillin.
NalbuphineProchlorperazine may increase the hypotensive activities of Nalbuphine.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Prochlorperazine.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Prochlorperazine.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Prochlorperazine.
NelfinavirThe metabolism of Prochlorperazine can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Prochlorperazine can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Prochlorperazine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of Prochlorperazine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of Prochlorperazine can be decreased when combined with Nilotinib.
NitrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrazepam.
Nitrous oxideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Nitrous oxide.
NormethadoneProchlorperazine may increase the hypotensive activities of Normethadone.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Prochlorperazine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Prochlorperazine.
OlanzapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olanzapine.
OlaparibThe metabolism of Prochlorperazine can be decreased when combined with Olaparib.
OlopatadineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ondansetron.
OpiumProchlorperazine may increase the hypotensive activities of Opium.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Prochlorperazine.
OrphenadrineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Prochlorperazine.
OsanetantThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Osanetant.
OsimertinibThe serum concentration of Prochlorperazine can be increased when it is combined with Osimertinib.
OxazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxazepam.
OxprenololProchlorperazine may increase the hypotensive activities of Oxprenolol.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Prochlorperazine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Oxybuprocaine.
OxycodoneProchlorperazine may increase the hypotensive activities of Oxycodone.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Prochlorperazine.
OxymorphoneProchlorperazine may increase the hypotensive activities of Oxymorphone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Prochlorperazine.
PalbociclibThe serum concentration of Prochlorperazine can be increased when it is combined with Palbociclib.
PaliperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paliperidone.
PanobinostatThe metabolism of Prochlorperazine can be decreased when combined with Panobinostat.
ParaldehydeProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Prochlorperazine.
ParoxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Prochlorperazine can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololProchlorperazine may increase the hypotensive activities of Penbutolol.
PentazocineProchlorperazine may increase the hypotensive activities of Pentazocine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Prochlorperazine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Prochlorperazine.
PerampanelThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Perphenazine.
PethidineProchlorperazine may increase the hypotensive activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Prochlorperazine.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Prochlorperazine.
PhenobarbitalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenoxyethanol.
PhentermineProchlorperazine may decrease the stimulatory activities of Phentermine.
PhenytoinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pimozide.
PindololProchlorperazine may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pomalidomide.
PosaconazoleThe metabolism of Prochlorperazine can be decreased when combined with Posaconazole.
PractololProchlorperazine may increase the hypotensive activities of Practolol.
PramipexoleProchlorperazine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prazepam.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Prochlorperazine.
PrilocaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prilocaine.
PrimaquineThe serum concentration of Prochlorperazine can be increased when it is combined with Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Primidone.
ProcaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Prochlorperazine.
ProguanilThe serum concentration of Prochlorperazine can be increased when it is combined with Proguanil.
PromazineThe metabolism of Prochlorperazine can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Prochlorperazine.
ProparacaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Propoxycaine.
PropranololProchlorperazine may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Prochlorperazine.
PSD502The risk or severity of adverse effects can be increased when Prochlorperazine is combined with PSD502.
PyrimethamineThe serum concentration of Prochlorperazine can be increased when it is combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quazepam.
QuetiapineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Quetiapine.
QuinacrineThe serum concentration of Prochlorperazine can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Prochlorperazine.
QuinidineThe serum concentration of Prochlorperazine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Prochlorperazine can be increased when it is combined with Quinine.
RadicicolThe serum concentration of Prochlorperazine can be increased when it is combined with Radicicol.
RamelteonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ramelteon.
RanolazineThe metabolism of Prochlorperazine can be decreased when combined with Ranolazine.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Prochlorperazine.
RemifentanilProchlorperazine may increase the hypotensive activities of Remifentanil.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Prochlorperazine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Prochlorperazine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Prochlorperazine.
RifabutinThe metabolism of Prochlorperazine can be increased when combined with Rifabutin.
RifampicinThe metabolism of Prochlorperazine can be increased when combined with Rifampicin.
RifapentineThe metabolism of Prochlorperazine can be increased when combined with Rifapentine.
RisperidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Risperidone.
RitonavirThe metabolism of Prochlorperazine can be decreased when combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Prochlorperazine.
RolapitantThe metabolism of Prochlorperazine can be decreased when combined with Rolapitant.
RomifidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Romifidine.
RopiniroleProchlorperazine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Prochlorperazine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Prochlorperazine.
RotigotineProchlorperazine may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Prochlorperazine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with S-Ethylisothiourea.
SaquinavirThe metabolism of Prochlorperazine can be decreased when combined with Saquinavir.
ScopolamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Prochlorperazine.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Prochlorperazine.
SertindoleThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sevoflurane.
SildenafilThe metabolism of Prochlorperazine can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Prochlorperazine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Prochlorperazine can be increased when it is combined with Simeprevir.
SinefunginThe serum concentration of Prochlorperazine can be increased when it is combined with Sinefungin.
Sodium oxybateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sodium oxybate.
SotalolProchlorperazine may increase the hypotensive activities of Sotalol.
St. John's WortThe serum concentration of Prochlorperazine can be decreased when it is combined with St. John's Wort.
StiripentolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Stiripentol.
SufentanilProchlorperazine may increase the hypotensive activities of Sufentanil.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prochlorperazine.
SulfadoxineThe serum concentration of Prochlorperazine can be increased when it is combined with Sulfadoxine.
SulfametopyrazineThe serum concentration of Prochlorperazine can be increased when it is combined with Sulfametopyrazine.
SulfisoxazoleThe metabolism of Prochlorperazine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Prochlorperazine.
SuvorexantThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Suvorexant.
tafenoquineThe serum concentration of Prochlorperazine can be increased when it is combined with tafenoquine.
TapentadolProchlorperazine may increase the hypotensive activities of Tapentadol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Prochlorperazine.
TasimelteonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tasimelteon.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Prochlorperazine.
TelaprevirThe metabolism of Prochlorperazine can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Prochlorperazine can be decreased when combined with Telithromycin.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Prochlorperazine.
TerbinafineThe metabolism of Prochlorperazine can be decreased when combined with Terbinafine.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Prochlorperazine.
TetracaineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tetrodotoxin.
ThalidomideProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Prochlorperazine.
ThiamylalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiagabine.
TiclopidineThe metabolism of Prochlorperazine can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tiletamine.
TimololProchlorperazine may increase the hypotensive activities of Timolol.
TipranavirThe metabolism of Prochlorperazine can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tizanidine.
TocilizumabThe serum concentration of Prochlorperazine can be decreased when it is combined with Tocilizumab.
TolcaponeThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Tolcapone.
TopiramateThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Topiramate.
TramadolProchlorperazine may increase the hypotensive activities of Tramadol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Prochlorperazine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prochlorperazine.
TrazodoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triazolam.
TrifluoperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triflupromazine.
TrimethoprimThe serum concentration of Prochlorperazine can be increased when it is combined with Trimethoprim.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Prochlorperazine.
TriprolidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Triprolidine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Prochlorperazine.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Prochlorperazine.
VerapamilThe metabolism of Prochlorperazine can be decreased when combined with Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vilazodone.
VoriconazoleThe metabolism of Prochlorperazine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Xylazine.
ZaleplonThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zaleplon.
ZiconotideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zimelidine.
ZiprasidoneThe metabolism of Prochlorperazine can be decreased when combined with Ziprasidone.
ZiprasidoneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Prochlorperazine.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Prochlorperazine.
ZonisamideThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Zuclopenthixol.
Food Interactions
  • Avoid alcohol.
  • Take with a full glass of water Avoid excessive quantities of coffee or tea (Caffeine).
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Roberge RJ: Antiemetic-related dystonic reaction unmasked by removal of a scopolamine transdermal patch. J Emerg Med. 2006 Apr;30(3):299-302. [PubMed:16677982 ]
  3. Hamik A, Peroutka SJ: Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytryptamine3 receptors. Cancer Chemother Pharmacol. 1989;24(5):307-10. [PubMed:2527092 ]
  4. Vinson DR: Development of a simplified instrument for the diagnosis and grading of akathisia in a cohort of patients receiving prochlorperazine. J Emerg Med. 2006 Aug;31(2):139-45. [PubMed:17044574 ]
  5. Callan JE, Kostic MA, Bachrach EA, Rieg TS: Prochlorperazine vs. promethazine for headache treatment in the emergency department: a randomized controlled trial. J Emerg Med. 2008 Oct;35(3):247-53. doi: 10.1016/j.jemermed.2007.09.047. Epub 2008 Jun 5. [PubMed:18534808 ]
  6. Narita M, Takei D, Shiokawa M, Tsurukawa Y, Matsushima Y, Nakamura A, Takagi S, Asato M, Ikegami D, Narita M, Amano T, Niikura K, Hashimoto K, Kuzumaki N, Suzuki T: Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. Eur J Pharmacol. 2008 Dec 14;600(1-3):105-9. doi: 10.1016/j.ejphar.2008.10.030. Epub 2008 Oct 21. [PubMed:18955042 ]
  7. Golembiewski J, Tokumaru S: Pharmacological prophylaxis and management of adult postoperative/postdischarge nausea and vomiting. J Perianesth Nurs. 2006 Dec;21(6):385-97. [PubMed:17169748 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23